Cyclooxygenase-1 (COX-1) is a key enzyme in the biosynthesis of proinflammatory thromboxanes and prostaglandins and is found in glial and neuronal cells within brain. COX-1 expression is implicated in numerous neuroinflammatory states. We aim to find a direct-acting positron emission tomography (PET) radioligand for imaging COX-1 in human brain as a potential biomarker of neuroinflammation and for serving as a tool in drug development. Seventeen 3-substituted 1,5-diaryl-1 H -1,2,4-triazoles were prepared as prospective COX-1 PET radioligands. From this set, three 1,5-(4-methoxyphenyl)-1 H -1,2,4-triazoles, carrying a 3-methoxy ( 5 ), 3-(1,1,1-trifluoroethoxy) ( 20 ), or 3-fluoromethoxy substituent ( 6 ), were selected for radioligand development, based mainly on their high affinities and selectivities for inhibiting human COX-1, absence of carboxyl group, moderate computed lipophilicities, and scope for radiolabeling with carbon-11 ( t 1/2 = 20.4 min) or fluorine-18 ( t 1/2 = 109.8 min). Methods were developed for producing [ 11 C]5, [ 11 C]20, and [ d 2 - 18 F] 6 from hydroxy precursors in a form ready for intravenous injection for prospective evaluation in monkey with PET.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: